A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed · Phase 1

Conditions studied: Hematologic Malignancy

In brief

This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.

Key facts

Study ID

NCT02352558

Run by

Sumitomo Pharma America, Inc.

People needed

15

Starts

2015-05-01

Expected to finish

2019-05-16

Last updated by the study team

2023-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• Indiana University — Indianapolis, Indiana, United States
• West Clinic — Germantown, Tennessee, United States
• Cancer Care Centers of South Texas — San Antonio, Texas, United States
• Cancer Care Centers of South Texas - HOAST — San Antonio, Texas, United States
• Virginia Cancer Specialists, P.C. — Fairfax, Virginia, United States
• Virginia Oncology Associates — Norfolk, Virginia, United States
• Northwest Cancer Specialists, PC — Vancouver, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.